Ned Davis Research projects Bitcoin could hit $170,000 by 2030 and $230,000 by 2035, based on seven valuation methods emphasizing network adoption and demand rather than just supply scarcity. Current Bitcoin prices near $76,000 are close to mining costs, highlighting near-term challenges amid ETF outflows and regulatory setbacks. The forecast depends heavily on increased investor adoption and demand growth, with measurable factors like active addresses and ETF exposure serving as indicators to watch.
Bitcoin price prediction is the subject, with Pluang market data providing context. For readers following cryptocurrency markets, 46 of 50 major cryptocurrencies rose and 3 fell today. Notable movers include UNI at Rp128.398 with an 18.81% increase and a Pluang order activity of 82% Sell / 18% Buy, KSM at Rp72.726 up 12.32% with 7% Sell / 93% Buy, and BAL at Rp16.297 up 11.14%. Data is as of Sep 17, 2026 21:23 WIB.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
